Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility
| Brand name | OPTASE |
| Generic name | GLYCERIN |
| Active ingredient(s) | GLYCERIN |
| Distributed by / for | Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA |
| NDC | 72972-002-01 |
| Full product label | Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01. |
| Recalling firm | SCOPE HEALTH |
| Distribution | Nationwide within the United States |
| Recall initiated | 2026-04-20 |
| Report date | 2026-05-06 |
| Recall completed | — |
| Recall number | D-0499-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | New York NY United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗